Strategic Focus Clinical stage biotech targeting inflammatory and immunological diseases with MARCKS inhibition, presenting a niche yet potentially high-impact opportunity for partnerships, licensing deals, and CRO collaborations to accelerate development timelines.

Recent Leadership Appointment of a new CEO in 2021 signals potential strategic pivots, possible fundraising rounds, and readiness to pursue collaborations or exit options that could align with BD efforts.

Favorable Traction Phase 2 data and ongoing ARDS and NSCLC programs indicate near-term clinical milestones that can be leveraged to initiate discussions with investors, strategic partners, or pharma companies seeking adjunctive inflammatory or oncology platforms.

Funding & Scale Funding of around 16 million and revenue in the low single digits suggests opportunities for co-development, grant partnerships, milestone-based collaborations, or larger pharma partnerships to de-risk late-stage trials.

Market Position Specialized MARCKS-targeting platform with potential applicability across inflammatory, respiratory, and oncological indications, offering a distinct value proposition for companies looking to expand across immunology or rare inflammatory diseases.